Seizure risk with repetitive TMS: Survey results from over a half-million treatment sessions
Autor: | Rebecca A. Betensky, Noam G. Newberger, Joseph J. Taylor, Daniel Z. Press, David Feifel, Angela Phillips, Adam P. Stern |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Risk
medicine.medical_specialty medicine.medical_treatment Biophysics Neurosciences. Biological psychiatry. Neuropsychiatry Poisson distribution 050105 experimental psychology 03 medical and health sciences symbols.namesake 0302 clinical medicine medicine 0501 psychology and cognitive sciences Prospective cohort study business.industry General Neuroscience 05 social sciences Interventional psychiatry Absolute risk reduction Sampling (statistics) Seizure Confidence interval Transcranial magnetic stimulation Study heterogeneity Relative risk symbols Physical therapy Neurology (clinical) Safety business 030217 neurology & neurosurgery RC321-571 |
Zdroj: | Brain Stimulation, Vol 14, Iss 4, Pp 965-973 (2021) |
Popis: | Background: Seizures are rare during repetitive transcranial magnetic stimulation (rTMS) treatment, but estimating risk is difficult because of study heterogeneity and sampling limitations. Moreover, there are few studies comparing rates between device manufacturers. Objective: The objective of this study was to calculate rTMS seizure rates across various FDA-cleared devices in naturalistic clinical settings. Methods: In July and August 2018, approximately 500 members of the Clinical TMS Society (CTMSS) were electronically surveyed about seizures in their practices. Seizures were distinguished from non-seizures by a remote semi-structured interview with a Board-certified neurologist and Co-Chair of the CTMSS Standards Committee. Exact Poisson calculations were used to estimate seizure rates and confidence intervals across the four most widely used manufacturers. Results: The survey was completed by 134 members, with 9 responses excluded because of data inconsistencies. In total, 18 seizures were reported in 586,656 sessions and 25,526 patients across all device manufacturers. The overall seizure rate was 0.31 (95% CI: 0.18, 0.48) per 10,000 sessions, and 0.71 (95% CI: 0.42, 1.11) per 1000 patients. The Brainsway H-coil seizure rate of 5.56 per 1000 patients (95% CI: 2.77,9.95) was significantly higher (p |
Databáze: | OpenAIRE |
Externí odkaz: |